Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma

Meyer Children's Hospital IRCCS95 enrolled

Overview

This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Neuroblastoma Ewing Sarcoma

Interventions

beta3 expressionDIAGNOSTIC_TEST

the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor

Eligibility

Sex: ALLMin age: 0 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of Ewing sarcoma or neuroblastoma Exclusion Criteria: * sieropositivity

Locations (1)

Laboratorio traslazionale in oncoematologia

Florence, Italy, Italy

Outcomes

Primary Outcomes

expression of beta3-adrenoreceptor

Time frame: from enrollment to the performance of the analysis that can take up to 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.